<?xml version='1.0' encoding='utf-8'?>
<document id="28983943"><sentence text="Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?"><entity charOffset="8-20" id="DDI-PubMed.28983943.s1.e0" text="methotrexate" /></sentence><sentence text="The aim of this retrospective cohort study was to investigate the incidence of delayed methotrexate elimination in patients treated with high-dose methotrexate (≥1 g/m2 ) for haematological malignancy and to identify the impact of interacting drugs, especially proton-pump inhibitors (PPIs) and ranitidine"><entity charOffset="87-99" id="DDI-PubMed.28983943.s2.e0" text="methotrexate" /><entity charOffset="147-159" id="DDI-PubMed.28983943.s2.e1" text="methotrexate" /><entity charOffset="295-305" id="DDI-PubMed.28983943.s2.e2" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.28983943.s2.e0" e2="DDI-PubMed.28983943.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28983943.s2.e0" e2="DDI-PubMed.28983943.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s2.e0" e2="DDI-PubMed.28983943.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28983943.s2.e1" e2="DDI-PubMed.28983943.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s2.e1" e2="DDI-PubMed.28983943.s2.e2" /></sentence><sentence text=" All patients treated with high-dose methotrexate over a 6 year period in the haematology department of the Lyon Sud University Hospital (Hospices Civils de Lyon, France) were included"><entity charOffset="37-49" id="DDI-PubMed.28983943.s3.e0" text="methotrexate" /></sentence><sentence text=" Potential risk factors for delayed methotrexate elimination were tested in a generalized linear model by univariate analysis: patient age, gender, methotrexate dose, administration of PPI or ranitidine, and concomitant nephrotoxic drugs"><entity charOffset="36-48" id="DDI-PubMed.28983943.s4.e0" text="methotrexate" /><entity charOffset="148-160" id="DDI-PubMed.28983943.s4.e1" text="methotrexate" /><entity charOffset="192-202" id="DDI-PubMed.28983943.s4.e2" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.28983943.s4.e0" e2="DDI-PubMed.28983943.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28983943.s4.e0" e2="DDI-PubMed.28983943.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s4.e0" e2="DDI-PubMed.28983943.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28983943.s4.e1" e2="DDI-PubMed.28983943.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s4.e1" e2="DDI-PubMed.28983943.s4.e2" /></sentence><sentence text=" A total of 412 cycles of methotrexate were administered to 179 patients"><entity charOffset="26-38" id="DDI-PubMed.28983943.s5.e0" text="methotrexate" /></sentence><sentence text=" Proton-pump inhibitors were co-administered with methotrexate in 127 cycles and ranitidine in 192 cycles"><entity charOffset="50-62" id="DDI-PubMed.28983943.s6.e0" text="methotrexate" /><entity charOffset="81-91" id="DDI-PubMed.28983943.s6.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.28983943.s6.e0" e2="DDI-PubMed.28983943.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28983943.s6.e0" e2="DDI-PubMed.28983943.s6.e1" /></sentence><sentence text=" Ninety-three cycles included no antacid drugs" /><sentence text=" A total of 918 plasma methotrexate assays were performed"><entity charOffset="23-35" id="DDI-PubMed.28983943.s8.e0" text="methotrexate" /></sentence><sentence text=" Methotrexate concentrations were checked at 24 hours in 92% of cycles"><entity charOffset="1-13" id="DDI-PubMed.28983943.s9.e0" text="Methotrexate" /></sentence><sentence text=" Delayed methotrexate elimination was observed in 20"><entity charOffset="9-21" id="DDI-PubMed.28983943.s10.e0" text="methotrexate" /></sentence><sentence text="9% of cycles" /><sentence text=" A total of 63 cycles with delayed methotrexate elimination were only identified on plasma methotrexate measures at 72 hours: ie, plasma methotrexate was in the normal range at 24 and 48 hour post injection"><entity charOffset="35-47" id="DDI-PubMed.28983943.s12.e0" text="methotrexate" /><entity charOffset="91-103" id="DDI-PubMed.28983943.s12.e1" text="methotrexate" /><entity charOffset="137-149" id="DDI-PubMed.28983943.s12.e2" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.28983943.s12.e0" e2="DDI-PubMed.28983943.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28983943.s12.e0" e2="DDI-PubMed.28983943.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s12.e0" e2="DDI-PubMed.28983943.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28983943.s12.e1" e2="DDI-PubMed.28983943.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s12.e1" e2="DDI-PubMed.28983943.s12.e2" /></sentence><sentence text=" Use of PPI/ranitidine or no antacid drugs did not increase risk of delayed elimination, with respectively delayed methotrexate elimination in 20"><entity charOffset="12-22" id="DDI-PubMed.28983943.s13.e0" text="ranitidine" /><entity charOffset="115-127" id="DDI-PubMed.28983943.s13.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.28983943.s13.e0" e2="DDI-PubMed.28983943.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28983943.s13.e0" e2="DDI-PubMed.28983943.s13.e1" /></sentence><sentence text="5%, 21" /><sentence text="9%, and 19" /><sentence text="4% of cycles (P = " /><sentence text="89)" /><sentence text=" Impaired baseline creatinine clearance showed significant association in univariate analysis"><entity charOffset="19-29" id="DDI-PubMed.28983943.s18.e0" text="creatinine" /></sentence><sentence text=" Fifteen patients showed grade 1 acute kidney injury, 1 grade 2, 2 grade 3, and none grade 4" /><sentence text=" For half of these cases, delayed methotrexate elimination was observed and the 2 grade 3 events appeared in patients treated with PPIs"><entity charOffset="34-46" id="DDI-PubMed.28983943.s20.e0" text="methotrexate" /></sentence><sentence text=" This retrospective study suggests that there is no association between concomitant use of proton-pump inhibitors (pantoprazole and esomeprazole) or ranitidine and delayed methotrexate elimination"><entity charOffset="115-127" id="DDI-PubMed.28983943.s21.e0" text="pantoprazole" /><entity charOffset="132-144" id="DDI-PubMed.28983943.s21.e1" text="esomeprazole" /><entity charOffset="149-159" id="DDI-PubMed.28983943.s21.e2" text="ranitidine" /><entity charOffset="172-184" id="DDI-PubMed.28983943.s21.e3" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e0" e2="DDI-PubMed.28983943.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e0" e2="DDI-PubMed.28983943.s21.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e0" e2="DDI-PubMed.28983943.s21.e2" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e0" e2="DDI-PubMed.28983943.s21.e3" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e1" e2="DDI-PubMed.28983943.s21.e1" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e1" e2="DDI-PubMed.28983943.s21.e2" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e1" e2="DDI-PubMed.28983943.s21.e3" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e2" e2="DDI-PubMed.28983943.s21.e2" /><pair ddi="false" e1="DDI-PubMed.28983943.s21.e2" e2="DDI-PubMed.28983943.s21.e3" /></sentence><sentence text="" /></document>